Patent · US Active

Engineered dendritic cells and uses for the treatment of cancer

US9675642B2 · kind B2 · utility

2Cited by

4References

7Claims

0Family size

Assignees

University of Pittsburgh—Of the Commonwealth System of Higher Education · US
INTREXON CORPORATION · US

Inventors

J. Mark Braughler · Pittsburgh, US
Prasanna Kumar · Frisco, US
Walter J. Storkus · Pittsburgh, US
Hideho Okada · Mill Valley, US

Key dates

Filing date	Jan 9, 2013
Grant date	Jun 13, 2017
Priority date	—
Expiry date	Jan 25, 2033

Classification

Technology area (CPC G)Physics
CPC primaryG01N2800/52
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

This invention provides the field of therapeutics. Most specifically present invention provides methods of generating in vitro engineered dendritic cells conditionally expressing interleukin-12 (IL-12) under the control of a gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals including human.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.